BOLT Bolt Bio: Bathi resik saben saham sajrone 12 wulan pungkasan

Bolt Biotherapeutics focuses on the safety of ISAC-conjugates for combating tumors. The business is underpinned by robotic test automation, as evidenced by the year-over-year (ttm) EPS trend, where the current value stands at 32.40. The company is currently minimizing expenses and developing only one primary drug, while excluding any merger and acquisition deals.
boltbio.com - rincian analitis lan metrik utama (BOLT)

This indicator measures the dynamics of net income per share over a rolling year, stripping fundamental metrics of short-term market noise. For Bolt Biotherapeutics (BOLT), which focuses on costly immunotherapy research without current revenues, the current EPS YoY TTM growth trend reflects the impact of capital injections and clinical costs, determining the company's overall capital resilience.